FDA approves genetic test for lung cancer drug

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

The diagnostic test is the first approved to detect found in roughly 10 percent of patients with the most prevalent form of lung cancer, known as non-small cell lung cancer.

Patients who test positive for the mutation are more likely to respond to Genentech's drug Tarceva as a first-choice treatment, and the FDA expanded the drug's approval for that use in an announcement Tuesday. The drug was previously approved only as a second-line option after patients had failed to respond to chemotherapy.

Lung cancer is the deadliest form of cancer among both men and women in the U.S.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New treatment holds promise for resistant lung cancer

Apr 09, 2013

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps ...

Recommended for you

Breakthrough to take the pain out of catheters

11 hours ago

A new pharmaceutical product that could significantly improve quality of life for catheter users all over the world is to be developed by Queen's University Belfast after it won a national award.

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.